D.E. Shaw & Co
OMIC

D.E. Shaw & Co’s Singular Genomics Systems, Inc. Common Stock OMIC Stock Holding History

D.E. Shaw & Co’s Portfolio OMIC Stock Details OMIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,715
Closed -$19.6K – 4698
2023
Q3 		$19.6K Buy
1,715
+357
+26% +$6.63K ﹤0.01% 3992
2023
Q2 		$33.8K Buy
1,358
+222
+20% +$6.5K ﹤0.01% 3918
2023
Q1 		$41.2K Sell
1,136
-398
-26% -$24.4K ﹤0.01% 4061
2022
Q4 		$92.5K Buy
1,534
+202
+15% +$13.5K ﹤0.01% 4378
2022
Q3 		$100K Sell
1,332
-6,002
-82% -$627K ﹤0.01% 4598
2022
Q2 		$840K Sell
7,334
-1,346
-16% -$158K ﹤0.01% 3746
2022
Q1 		$1.64M Buy
8,680
+6,821
+367% +$1.58M ﹤0.01% 3502
2021
Q4 		$645K Buy
1,859
+770
+71% +$298K ﹤0.01% 4250
2021
Q3 		$366K Buy
+1,089
New +$558K ﹤0.01% 4252

Other funds holding OMIC

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
QM
QVIDTVM Management The Woodlands, Texas $81.4M AUM 2.94% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co's OMIC Position: Q4 2023 in Review

D.E. Shaw & Co sold out of Singular Genomics Systems, Inc. Common Stock (OMIC) in Q4 2023, closing a stake of 1,715 shares — an estimated $19.6K sold.

D.E. Shaw & Co first reported a position in OMIC in Q3 2021 and held it in 9 quarters. The position peaked at $1.64M in Q1 2022. 47 funds tracked by Wall St. Rank hold OMIC as of Q4 2023.

  • D.E. Shaw & Co reported no remaining Singular Genomics Systems, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • D.E. Shaw & Co sold 1,715 Singular Genomics Systems, Inc. Common Stock shares in Q4 2023, an estimated $19.6K.
  • D.E. Shaw & Co first reported a position in Singular Genomics Systems, Inc. Common Stock in Q3 2021 and held it in 9 quarters.
  • D.E. Shaw & Co's Singular Genomics Systems, Inc. Common Stock position peaked at $1.64M in Q1 2022.
  • 47 funds tracked by Wall St. Rank held Singular Genomics Systems, Inc. Common Stock as of Q4 2023.

Based on D.E. Shaw & Co's 13F filing for Q4 2023, filed 14 Feb 2024.